依达拉奉联合阿加曲班治疗进展性脑梗死临床观察

Clinical observation of edaravone combined with argatroban in the treatment of progressive cerebral infarction

目的探讨依达拉奉与阿加曲班联合治疗进展性脑梗死(PCI)的疗效和安全性。方法 70例PCI患者,随机分成治疗组和对照组。治疗组36例,给予依达拉奉和阿加曲班;对照组34例仅给予阿加曲班。以治疗前后神经功能缺损评分评价有效率,并检查血、尿常规,肝、肾功能及心电图,以监测不良反应。结果治疗组患者神经功能缺损评分改善(P<0.01),且治疗组临床总有效率优于对照组(P<0.05)。所有病例均未见明显不良反应。结论依达拉奉联合阿加曲班治疗PCI有效且安全。

Objective To observe the clinical effects of edaravone combined with argatroban for the progressive cerebral infarction （PCI）. Methods Seventy PCI patients were recruited and randomly divided into treatment group （administered with edaravone and argatroban, n=36） and control group （administered with argatroban only, n=34）. Curative effect was evaluated by neurological function deficit scale and clinical manifestation. The blood and urinary routine test, liver function, renal function and electrocardiogram were also carried out before and after the treatment to detect the adverse drug reactions （ADRs）. Results The grade of neurological function deficit scale in treatment group were improved significantly after treatment （P〈 0.01）. There was difference between treatment group and control group for overall response rate （P〈0.05） and there were no ADRs in both groups. Conclusion Edaravone combined with argatroban is an effective and safe therapeutic regimen for PCI patients.